The company posted Q4 revenues of $10.9 million, up from $6.6 million in Q4 2017, beating the consensus Wall Street estimate of $9.3 million.
University of Kansas researchers developed the technology, which could enable faster, more sensitive analysis of exosomes than existing microfluid platforms.
However, a shift within the field towards experiments comprising larger numbers of samples and conditions may give DIA an advantage in the future.
In a recent study, researchers combined genomic and proteomic data to identify mutations responsible for a pair of rare monogenic neutrophil diseases.
The company reported revenues of $553.6 million, up from $530.5 million in Q4 2017, and beating the average analyst estimate of $544.6 million.
Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.
The firms will cooperatively promote Indica's HALO image analysis tools with Fluidigm's Hyperion imaging mass cytometry platform and related products.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
The Swiss firm's ScaiVision software identifies disease-linked cells using AI, data visualization, and automation of hypothesis testing.
In 2018 Thermo Fisher posted $24.36 billion in revenues, up 16 percent from $20.92 billion in 2017 and beating the consensus analyst estimate of $24.08 billion.
The researchers presented new reagents and software for de novo peptide sequencing, an emerging technology with potential in proteomics and biopharma.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
In initial testing, the approach distinguished between stage I cancer cases and healthy controls with 95 percent sensitivity and 100 percent specificity.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
The subtypes — which were distinguished from one another using proteomic data — were associated with proliferation, immune response, metabolism, and invasion.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Cell Guidance Systems will use Expedeon's Lightning-Link Rapid Biotin reagent kit in the development of its TRIFic exosome immunoassay technology.
The partners will work to find novel proteins, including DNA endonucleases, to develop new gene editing therapies for cystic fibrosis and other diseases.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.